4-Amino-1-methyl-3-phenylindazol | 59944-84-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-Amino-1-methyl-3-phenylindazol
• 英文别名: 1-methyl-3-phenyl-1H-indazol-4-ylamine；1-Methyl-3-phenylindazol-4-amine
• CAS: 59944-84-2
• 化学式: C₁₄H₁₃N₃
• 分子量: 223.277
• InChiKey: ILPVJFXIFDOZPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (NE)-N-(1-methyl-3-phenyl-6,7-dihydro-5H-indazol-4-ylidene)hydroxylamine 以67%的产率得到
  参考文献：
  名称：

  BARDAKOS V.; SUCROW W., CHEM. BER. , 1976, 109, NO 5, 1898-1910

  摘要：

  DOI：

文献信息

• High affinity inhibitors for target validation and uses thereof
  申请人：Princeton University

  公开号：EP1321467A2

  公开（公告）日：2003-06-25

  An inhibitor that does not inhibit a catalytic activity of a wild-type protein kinase but inhibits the same catalytic activity of the corresponding mutant protein kinase, wherein the wild-type protein kinase and the mutant protein kinase are functionally similar.

  一种抑制剂，它不能抑制野生型蛋白激酶的催化活性，但能抑制相应突变型蛋白激酶的相同催化活性，其中野生型蛋白激酶和突变型蛋白激酶在功能上相似。
• HIGH AFFINITY INHIBITORS FOR TARGET VALIDATION AND USES THEREOF
  申请人：Princeton University

  公开号：EP1140938A2

  公开（公告）日：2001-10-10
• US6383790B1
  申请人：——

  公开号：US6383790B1

  公开（公告）日：2002-05-07
• [EN] HIGH AFFINITY INHIBITORS FOR TARGET VALIDATION AND USES THEREOF<br/>[FR] INHIBITEURS DE HAUTE AFFINITE POUR LA VALIDATION DE CIBLES, ET LEURS UTILISATIONS
  申请人：UNIV PRINCETON

  公开号：WO2000042042A2

  公开（公告）日：2000-07-20

  This invention provides general methods for discovering mutant inhibitors for any class of enzymes as well as the specific inhibitors so identified. More specifically, this invention provides general methods for discovering specific inhibitors for multi-substrate enzymes. Examples of such multi-substrate enzymes include, but are not limited to, kinases and transferases. The mutant inhibitors identified by the methods of this invention can be used to highly selectively disrupt cell functions such as oncogenic transformation. In one particular example, this invention provides an Src protein kinase inhibitor, pharmaceutical compositions thereof and methods of disrupting transformation in a cell that expresses the target v-scr comprising contacting the cell with the protein kinase inhibitor.